Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects[1].
BI-505（1 ng/mL-1000 μg/mL）剂量依赖性地诱导表达 ICAM-1 的 Ramos、Raji 和 Daudi 淋巴瘤细胞的程序性细胞死亡 (PCD)[1]。
Bersanlimab（BI-505；20 mg/kg；腹腔注射；每周两次；持续 21 天）显着减少肿瘤生长并延长动物存活期[1]。
| Animal Model: | SCID mice injected with ARH-77 cells[1] |
| Dosage: | 20 mg/kg |
| Administration: | i.p.; twice-weekly; for 21 days |
| Result: | Significantly reduced tumor growth and prolonged animal survival. |
[1]. Niina VeitonmÄki, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15.